TY - JOUR
T1 - Anti‐anti‐IgE idiotypic antibodies mimic IgE in their binding to the Fcϵ receptor
AU - Baniyash, Michal
AU - Eshhar, Zelig
PY - 1987
Y1 - 1987
N2 - The binding site of some anti‐idiotypic antibodies (anti‐Id) can appear as a structural image of the antigen and as such may mimic its biologic activity. We raised anti‐anti‐IgE antibodies in an attempt to obtain anti‐Id capable of interacting with the Fcϵ receptor (FcϵR). Guinea pigs were immunized with purified murine monoclonal antibodies (mAb) that had been found to react with epitopes closely related to the site on the IgE molecule which is recognized by the FcϵR. After only two injections, we could detect in the immune sera anti‐Id that inhibited the binding of IgE to the anti‐IgE mAb used as immunogens. However, only after 10 immunizations over a period of about 6 months could we detect antibodies that competed efficiently with the binding of IgE to rat basophilic leukemia (RBL) cells. The “IgE‐like” anti‐Id could be affinity purified from immunosorbents made of the anti‐IgE mAb. F(ab′)2 and Fab′ fragments were as effective inhibitors of IgE binding as the intact anti‐anti‐Id antibodies. Some of the anti‐Id caused RBL degranulation and all of them, like IgE, inhibited the binding of specific anti‐FcϵR mAb to RBL cells. In summary, by hyperimmunization with anti‐IgE mAb we could obtain anti‐Id whose antigen‐binding site is recognized by the mast cell receptor specific to the Fc portion of IgE.
AB - The binding site of some anti‐idiotypic antibodies (anti‐Id) can appear as a structural image of the antigen and as such may mimic its biologic activity. We raised anti‐anti‐IgE antibodies in an attempt to obtain anti‐Id capable of interacting with the Fcϵ receptor (FcϵR). Guinea pigs were immunized with purified murine monoclonal antibodies (mAb) that had been found to react with epitopes closely related to the site on the IgE molecule which is recognized by the FcϵR. After only two injections, we could detect in the immune sera anti‐Id that inhibited the binding of IgE to the anti‐IgE mAb used as immunogens. However, only after 10 immunizations over a period of about 6 months could we detect antibodies that competed efficiently with the binding of IgE to rat basophilic leukemia (RBL) cells. The “IgE‐like” anti‐Id could be affinity purified from immunosorbents made of the anti‐IgE mAb. F(ab′)2 and Fab′ fragments were as effective inhibitors of IgE binding as the intact anti‐anti‐Id antibodies. Some of the anti‐Id caused RBL degranulation and all of them, like IgE, inhibited the binding of specific anti‐FcϵR mAb to RBL cells. In summary, by hyperimmunization with anti‐IgE mAb we could obtain anti‐Id whose antigen‐binding site is recognized by the mast cell receptor specific to the Fc portion of IgE.
UR - http://www.scopus.com/inward/record.url?scp=0023265289&partnerID=8YFLogxK
U2 - 10.1002/eji.1830170918
DO - 10.1002/eji.1830170918
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 2443366
AN - SCOPUS:0023265289
SN - 0014-2980
VL - 17
SP - 1337
EP - 1342
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 9
ER -